scholarly journals Assessment of Bone Marrow Fibrosis and Angiogenesis in Monitoring Patients With Multiple Myeloma

2012 ◽  
Vol 137 (6) ◽  
pp. 870-878 ◽  
Author(s):  
Emina Babarović ◽  
Toni Valković ◽  
Sanja Štifter ◽  
Ivana Budisavljević ◽  
Irena Seili-Bekafigo ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Bone Marrow Fibrosis ◽  
Marrow Fibrosis

The presence of bone marrow fibrosis is associated with poorer prognosis in newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e19514-e19514
Author(s):  
Barry Paul ◽  
Gavin Loitsch ◽  
Daniel Feinberg ◽  
Ian Barak ◽  
Zhiguo Li ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Poor Prognosis ◽  
Proteasome Inhibitors ◽  
Cell Transplant ◽  
Newly Diagnosed ◽  
Bone Marrow Fibrosis ◽  
Bone Marrow Biopsies ◽  
Immunomodulatory Agents ◽  
Marrow Fibrosis

e19514 Background: The treatment of newly diagnosed multiple myeloma (NDMM) has evolved significantly with the advent of the immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs). While the presence of bone marrow fibrosis (BMF) has previously been associated with poor prognosis in multiple myeloma (MM), these studies were small and conducted prior to the widespread use of IMiDs and PIs. Here, we determined the incidence of BMF in NDMM patients and correlated the degree of BMF with prognosis in a population enriched for IMiD and/or PI exposure. Methods: Bone marrow biopsies from 306 MM patients seen at Duke between 2003 and 2013 were screened for BMF using a reticulin stain. Samples were scored as absent, mild, moderate, or severe fibrosis based on the degree and intensity of staining. The association between presence and degree of BMF to progression free survival (PFS) and overall survival (OS) was calculated using Kaplan-Meier analysis. Results: Of the 306 patients evaluated, 248 (81.0%) were treated with an IMiD, 241 (78.8%) were treated with a PI, and 217 (70.9%) received both. Additionally, 160 (52.3%) patients went on to receive an autologous stem cell transplant (HSCT). A total of 193 patients (63.1%) were evaluable for BMF. Of these, 96 (49.7%) had detectable BMF, while 97 (50.3%) had no BMF. The degree of BMF was mild in 60 patients (62.5%), and moderate or severe in 34 patients (35.4%). Median PFS in patients without BMF was 30.4 months, and 21.8 months in patients with BMF present (log-rank p = 0.02). Median OS was 61.1 months in patients without BMF, and 46.3 months in patients with BMF (log-rank p = 0.048). Patients with moderate or severe BMF had a particularly poor prognosis with a PFS of only 18.8 months and an OS of 32.7 months. Conclusions: Our study represents the largest dataset to date examining the incidence of BMF in MM patients, and is the only one to examine the association of BMF with prognosis in the era of novel therapies and widespread use of HSCT. Our data suggests that BMF is common in NDMM, and MM patients with BMF (particularly those with more extensive BMF) have a poorer prognosis even when treated with IMiDs and PIs. These data emphasize the importance of determining the presence and degree of BMF at time of MM diagnosis, and suggest a role for adjunctive therapies that target BMF in MM patients with co-existing BMF.

Monitoring of multiple myeloma and bone marrow fibrosis with aminoterminal propeptide of type III collagen (PIIINP)

1992 ◽  
Vol 82 (1) ◽  
pp. 32-37 ◽  
Author(s):  
Taina Taube ◽  
Kaarle Franssila ◽  
Leila Risteli ◽  
Juha Risteli and ◽  
Inkeri Elomaa
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Type Iii Collagen ◽  
Bone Marrow Fibrosis ◽  
Type Iii ◽  
Marrow Fibrosis

Bone Marrow Fibrosis In Patients With Multiple Myeloma: A New Prognostic Factor For Survival?

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 1946-1946 ◽  
Author(s):  
Tinna Hallgrimsdottir ◽  
Anna Porwit ◽  
Magnus Björkholm ◽  
Eva Rossmann ◽  
Hlif Steingrimsdottir ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Plasma Cells ◽  
Cox Regression ◽  
Conflicts Of Interest ◽  
University Hospital ◽  
Bone Marrow Fibrosis ◽  
Significant Difference ◽  
The Difference ◽  
Marrow Fibrosis

Abstract Introduction Multiple myeloma (MM) is characterized by the proliferation of plasma cells in the bone marrow and a secretion of monoclonal immunoglobulins. Survival in MM is very variable and multiple factors are known to influence prognosis such as age, ISS stage, and genetic abnormalities. Fibrosis can be found in the bone marrow of MM patients but the literature reporting the incidence of fibrosis and its effect on prognosis is very limited. The purpose of this study was to estimate the incidence of bone marrow fibrosis in MM patients and its effect on survival. Materials and methods Data was collected at the Karolinska University Hospital in Solna, Sweden and information obtained from the hospital's records. We gathered information on all patients diagnosed with MM between 2003 and 2011. All bone marrow reports were reviewed and the presence of bone marrow fibrosis (evaluated using reticulin staining) at diagnosis was recorded. Fibrosis was graded as 1 (mild), 2 (significant) and 3 (advanced), in accordance with WHO 2008 criteria. Patients with fibrosis were paired with patients without fibrosis (matched by sex, birth year, and year of diagnosis). Survival comparing MM patients with and without fibrosis was evaluated using Kaplan-Meier estimate and Cox regression model. Results A total of 586 individuals, 327 males and 259 females, were diagnosed with MM at the Karolinska University Hospital, Solna during 2003 – 2011. Evidence of bone marrow fibrosis was noted in 223 (38%) patients at diagnosis, and 175 had fibrosis grade 1, 33 grade 2, and 15 grade 3. No significant difference was observed between males (N = 135) and females (N = 88) (p = 0.085). Mean age at diagnosis was significantly lower for patients with fibrosis (67.1 years) than in patients without fibrosis (69.7 years) (p = 0.013). Compared with paired patients without fibrosis (N = 217), patients with fibrosis had significantly worse survival (Figure), being 5.0 years vs. 4.4 years, respectively (relative risk (RR)=1.3, 95% confidence interval (CI) 1.00-1.70; p= 0.049). The difference was greatest in male patients and patients younger than 65 years at diagnosis. Survival was worse in patients with advanced fibrosis, 4.5 (95% CI 3.6-6.4) years for grade 1 fibrosis, and 3.0 (95% CI 1.6-NA) years for higher degree of fibrosis. Conclusion In this study, based on almost 600 patients with MM we show that bone marrow fibrosis is common at diagnosis (38%). Importantly, our findings show that the presence of fibrosis was associated with inferior survival. More studies are needed regarding the underlying causes for these findings, including treatment response, treatment-related complications and relation to other known prognostic factors. Disclosures: No relevant conflicts of interest to declare.

Significance of bone marrow fibrosis in multiple myeloma

Pathology ◽  
2007 ◽  
Vol 39 (5) ◽  
pp. 512-515 ◽  
Author(s):  
Rajiv Subramanian ◽  
Debdatta Basu ◽  
Tarun K. Dutta
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Bone Marrow Fibrosis ◽  
Marrow Fibrosis

Bone Marrow Fibrosis in Multiple Myeloma

1988 ◽  
Vol 90 (6) ◽  
pp. 753-753 ◽  
Author(s):  
A. Riccardi ◽  
G. Ucci ◽  
A. Coci ◽  
E. Ascari
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Bone Marrow Fibrosis ◽  
Marrow Fibrosis

Bone marrow fibrosis and disease activity in multiple myeloma monitored by the aminoterminal propeptide of procollagen III in serum

1997 ◽  
Vol 99 (3) ◽  
pp. 641-648 ◽  
Author(s):  
N. Abildgaard ◽  
K. Bendix-Hansen ◽  
J. E. Kristensen ◽  
T. Vejlgaard ◽  
L. Ristelli ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Disease Activity ◽  
Bone Marrow Fibrosis ◽  
Marrow Fibrosis ◽  
Procollagen Iii

scholarly journals The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors

2020 ◽  
Vol 9 (16) ◽  
pp. 5869-5880
Author(s):  
Barry Paul ◽  
Yue Zhao ◽  
Gavin Loitsch ◽  
Daniel Feinberg ◽  
Parker Mathews ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Clinical Outcomes ◽  
Proteasome Inhibitors ◽  
Newly Diagnosed ◽  
Bone Marrow Fibrosis ◽  
Immunomodulatory Agents ◽  
The Impact ◽  
Marrow Fibrosis
Sign in / Sign up

Export Citation Format

Share Document